Id: acc3699
Group: 1sens
Protein: pRb
Gene Symbol: RB1
Protein Id: P06400
Protein Name: RB_HUMAN
PTM: phosphorylation
Site: Ser780
Site Sequence: YASTRPPTLSPIPHIPRSPYK
Disease Category: Respiratory system diseases
Disease: Airway Smooth Muscle Hyperplasia
Disease Subtype:
Disease Cellline:
Disease Info:
Drug: SB 203580
Drug Info: SB 203580 is a well - known p38 mitogen - activated protein kinase inhibitor. It is often used in biological and medical research.
Effect: modulate
Effect Info: "The p38MAPK inhibitor SB 203580 significantly inhibits the phosphorylation of p38MAPK and pRb induced by bFGF, thereby suppressing the cell cycle progression and proliferation. This suggests that p38MAPK plays a crucial role in bFGF-induced HASM proliferation."
Note:
Score: 4.0
Pubmed(PMID): 15249425
Sentence Index:
Sentence:

Sequence & Structure:

MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
RB1-Ser780
Cancer Intensity
BRCA
COAD 0.203
HGSC 0.883
ccRCC
GBM
HNSC -1.086
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 780 D Meningioma Phosphorylation 31615938
S 780 P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 16648554
S 780 U Breast cancer Phosphorylation 36797347
S 780 U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 15349907
S 780 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 23408967

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Nintedanib 8.9824 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Gefitinib 6.7385 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 AZD8055 8.7603 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 AZD8055 8.3011 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 AZD8055 6.8685 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Dactolisib 9.6522 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Dactolisib 6.7151 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 Dactolisib 6.0252 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 Dasatinib 8.8516 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Dasatinib 8.0264 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Dasatinib 7.2322 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Dasatinib 7.2162 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 Dasatinib 7.0393 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Nintedanib 10.6682 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A431 Gefitinib 7.2552 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 PD325901 11.037 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 PD325901 8.2246 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 PD325901 8.0368 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Pictilisib 8.7663 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 Refametinib 8.2982 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Refametinib 8.2688 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Refametinib 7.2106 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Staursporin 9.4929 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Staursporin 6.9696 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A549 Tideglusib 10.7566 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A549 Tideglusib 7.9558 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A549 Tideglusib 6.7551 -
P06400 RB1 P Ser780;Tyr790;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRSPY(ph)KFPS(ph)SPLR A431 Dasatinib 10.8417 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Afatinib 9.2363 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Afatinib 7.279 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Afatinib 8.9476 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A431 Afatinib 7.7291 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Afatinib 5.2963 -
P06400 RB1 P Ser780;Tyr790;Ser795 TNILQYASTRPPTLS(ph)PIPHIPRSPY(ph)KFPSS(ph)PLR A431 Afatinib 4.641 -
P06400 RB1 P Ser780;Ser788;Ser795 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR A431 Afatinib 5.5726 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Afatinib 5.4915 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Afatinib 5.4779 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A431 Afatinib 2 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Dasatinib 13.013 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Dasatinib 12.4658 -
P06400 RB1 P Ser780;Ser788;Ser795 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR A431 Afatinib 6.4091 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Dasatinib 9.4998 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Dasatinib 5.6719 -
P06400 RB1 P Ser780;Ser788;Ser794 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPS(ph)SPLR A431 Dasatinib 10.6843 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Dasatinib 7.0447 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Dasatinib 6.3067 -
P06400 RB1 P Ser780;Ser788;Ser795 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR A431 Gefitinib 8.0046 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Gefitinib 7.0223 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Gefitinib 6.2617 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Gefitinib 7.2727 -
P06400 RB1 P Ser780 TNILQYASTRPPTLS(ph)PIPHIPR A431 Gefitinib 6.8724 -
P06400 RB1 P Ser780;Ser788 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYK A431 Gefitinib 6.5685 -
P06400 RB1 P Ser780;Ser788;Ser795 TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR A431 Gefitinib 5.3441 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: